Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval Notice

About this update from Jiangsu Kanion Pharmaceutical Co. Ltd. Class A

Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval NoticeThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Jiangsu Kanion Pharmaceutical Co. Ltd. Class A